These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 30659018)
21. HIV moments and pre-exposure prophylaxis--Authors' reply. Dunn DT; Gafos M; White E; McCormack S Lancet; 2016 Apr; 387(10027):1508. PubMed ID: 27115971 [No Abstract] [Full Text] [Related]
22. Scotland's approval of PrEP creates postcode lottery in UK, say campaigners. Christie B BMJ; 2017 Apr; 357():j1834. PubMed ID: 28400382 [No Abstract] [Full Text] [Related]
23. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. Knox DC; Anderson PL; Harrigan PR; Tan DH N Engl J Med; 2017 Feb; 376(5):501-502. PubMed ID: 28146652 [No Abstract] [Full Text] [Related]
24. HIV preexposure prophylaxis in Canadian primary care and community settings. Heendeniya A; Tumarkin E; Bogoch II Can Fam Physician; 2019 Apr; 65(4):271-272. PubMed ID: 30979761 [No Abstract] [Full Text] [Related]
25. Primary HIV-1 infection in users of pre-exposure prophylaxis. Ambrosioni J; Petit E; Liegeon G; Laguno M; Miró JM Lancet HIV; 2021 Mar; 8(3):e166-e174. PubMed ID: 33316212 [TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
27. A case study of chewed Truvada Lalley-Chareczko L; Clark D; Zuppa AF; Moorthy G; Conyngham C; Mounzer K; Koenig H Antivir Ther; 2017; 22(7):639-641. PubMed ID: 28260694 [TBL] [Abstract][Full Text] [Related]
28. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM; Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965 [TBL] [Abstract][Full Text] [Related]
29. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE; BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073. Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932 [TBL] [Abstract][Full Text] [Related]
31. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B; AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400 [TBL] [Abstract][Full Text] [Related]
32. Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States. Rosenberg ES; Marcus JL Ann Epidemiol; 2018 Dec; 28(12):830-832. PubMed ID: 30224292 [No Abstract] [Full Text] [Related]
33. Stop stalling and make PrEP for HIV available now. Gold D BMJ; 2016 Jun; 353():i3160. PubMed ID: 27269364 [No Abstract] [Full Text] [Related]
34. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
35. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K; Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265 [TBL] [Abstract][Full Text] [Related]
36. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP. Highleyman L Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333 [No Abstract] [Full Text] [Related]
37. PrEP on Twitter: Information, Barriers, and Stigma. Schwartz J; Grimm J Health Commun; 2017 Apr; 32(4):509-516. PubMed ID: 27295507 [TBL] [Abstract][Full Text] [Related]
38. Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men. Grov C; Whitfield TH; Rendina HJ; Ventuneac A; Parsons JT AIDS Behav; 2015 Dec; 19(12):2234-44. PubMed ID: 25735243 [TBL] [Abstract][Full Text] [Related]